| Website | calithera.com |
| Category | BioTech |
| info@Calithera.com | |
| Employees | |
| Founded | 2010 |
| TOTAL | $40M |
| FUNDING TOTAL | $40M |
| Series A, 7/10 Morgenthaler Ventures U.S. Venture Partners Advanced Technology Ventures Delphi Ventures Mission Bay Capital | $40M |
Calithera Biosciences was founded in 2010, with core technologies licensed from the University of California, San Francisco, to develop novel therapeutic approaches to the treatment of cancer. The company is developing small molecules that directly activate caspases, the proteases responsible for initiating programmed cell death, or apoptosis, in cancer cells. Calithera plans to develop activators of additional enzymes as therapeutic agents for the treatment of cancer and other proliferative diseases. Located in South San Francisco, CA, Calithera Biosciences is privately held with backing from Morgenthaler Ventures, U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital.
